Markov model in evaluating the efficiency of various COVID-19 treatment regimens

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To consider the evidence-based approaches to treating virus-associated lung tissue lesions, the rationale for using the Markov model to evaluate the clinical and economic efficacy of interleukin (IL)-6 (IL-6) receptor inhibitors in patients with COVID-19.

Subjects and methods. To evaluate the clinical and economic effectiveness of using the receptor inhibitors in COVID-19 patients, the investigators formed two groups: 1) 187 patients received the standard therapy; 2) 104 patients had IL-6 receptor inhibitors in addition to the standard therapy.

Results and conclusion. The logistic regression method was used to determine the need for prescribing these drugs depending on the individual characteristics of patients, the key points were the length of a patient's stay in the intensive care unit, as well as the duration of oxygen support. In the context of new challenges to the healthcare system, it is necessary to further search for comprehensive methods of monitoring the condition and prognosis with promising ways to assess the validity of using therapeutic procedures and drugs.

Full Text

Restricted Access

About the authors

Е. S. Vdoushkina

Samara State Medical University, Ministry of Health of Russia

Email: borodulinbe@yandex.ru
ORCID iD: 0000-0003-0039-6829

Candidate of Medical Sciences

Russian Federation, Samara

E. A. Borodulina

Samara State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: borodulinbe@yandex.ru
ORCID iD: 0000-0002-3063-1538

MD, Professor

Russian Federation, Samara

E. P. Gladunova

Samara State Medical University, Ministry of Health of Russia

Email: borodulinbe@yandex.ru
ORCID iD: 0000-0002-8137-7197

PharmD, Associate Professor

Russian Federation, Samara

L. V. Povalyaeva

Samara State Medical University, Ministry of Health of Russia

Email: borodulinbe@yandex.ru
ORCID iD: 0000-0002-2546-1837

Candidate of Medical Sciences

Russian Federation, Samara

References

  1. Горенков Д.В., Хантимирова Л.М., Шевцов В.А. и др. Вспышка нового инфекционного заболевания COVID-19: β-коронавирусы как угроза глобальному здравоохранению. БИОпрепараты. Профилактика, диагностика, лечение. 2020; 20 (1): 6–20 [Gorenkov D.V., Khantimirova L.M., Shevtsov V.A. et al. An Outbreak of a New Infectious Disease COVID-19: β-coronaviruses as a Threat to Global Healthcare. BIOpreparations. Prevention, Diagnosis, Treatment. 2020; 20 (1): 6–20 (in Russ.)]. doi: 10.30895/2221-996X-2020-20-1-6-20
  2. Широбоков Я.Е., Гладунова Е.П., Бородулина Е.А. и др. Обзор потенциальных препаратов для антивирусной и упреждающей противоспалительной терапии новой коронавирусной инфекции, вызванной вирусом SARS-CoV-2. Acta Biomedica Scientifica. 2021; 6 (4): 74–86 [Shirobokov Y.E., Gladunova E.P., Borodulina E.A. et al. Overview of potential drugs for the treatment of new coronavirus Infection (COVID-19). Acta Biomedica Scientifica. 2021; 6 (4): 74–86 (in Russ.)]. doi: 10.29413/ABS.2021-6.4.7
  3. Гладунова Е.П., Широбоков Я.Е., Бородулина Е.А. Анализ ассортимента лекарственных препаратов и объема их потребления у пациентов старших возрастных групп с диагнозом COVID-19. Аспирантский Вестник Поволжья. 2021; 5–6: 161–6 [Gladunova E.P., Shirobokov Ya.E., Borodulina E.A. Analysis of drugs assortment and their consumption in older age patients diagnosed with COVID-19. Aspirantskiy Vestnik Povolzhiya. 2021; 5-6: 161–6 (in Russ.)]. doi: 10.55531/2072-2354.2021.21.3.161-166
  4. Бубнова М.Г., Аронов Д.М. COVID-19 и сердечно-сосудистые заболевания: от эпидемиологии до реабилитации. Пульмонология. 2020; 30 (5): 688–99 [Bubnova M.G., Aronov D.M. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. PULMONOLOGIYA. 2020; 30 (5): 688–99 (in Russ.)]. doi: 10.18093/0869-0189-2020-30-5-688-699
  5. Bousquet J., Zuberbier T., Cristol J.-P. et al. NRF2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clin Transl Allergy. 2020; 10 (1): 58. doi: 10.1186/s13601-020-00362-7
  6. Хаджиева М.Б., Грачева А.С., Ершов А.В. и др. Биомаркеры повреждения структур аэрогематического барьера при COVID-19. Общая реаниматология. 2021; 17 (3): 16–31 [Khadzhieva M.B., Gracheva A.S., Ershov A.V. et al. Biomarkers of Air-Blood Barrier Damage In COVID-19. General Reanimatology. 2021; 17 (3): 16–31 (in Russ.)]. doi: 10.15360/1813-9779-2021-3-2-0
  7. Ayinde O., Usman B., Posi A. et al. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19). China CDC Weekly. 2020; 2 (8): 113–22. doi: 10.46234/ccdcw2020.032
  8. Дедов Д.В. Новая коронавирусная инфекция (COVID-19): эпидемиология, клиническая характеристика больных, риск осложнений, профилактика, применение селенсодержащих препаратов. Врач. 2022; 33 (5): 58–62 [Dedov D. Novel coronavirus infection (COVID-19): epidemiology, clinical characteristics of patients, risk of complications, prevention, use of selenium-containing drugs. Vrach. 2022; 33 (5): 58–62 (in Russ.)] doi: 10.29296/25877305-2022-05-12
  9. Гриневич В.Б., Лазебник Л.Б., Кравчук Ю.А. и др. Поражения органов пищеварения при постковидном синдроме. Клинические рекомендации. Экспериментальная и клиническая гастроэнтерология. 2022; 12: 4–68 [Grinevich V.B., Lazebnik L.B., Kravchuk Yu.A. et al. Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines. Experimental and Clinical Gastroenterology. 2022; 12: 4–68 (in Russ.)]. doi: 10.31146/1682-8658-ecg-208-12-4-68
  10. Ciceri F., Castagna A., Rovere-Querini P. et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020; 217: 108509. doi: 10.1016/j.clim.2020.108509
  11. Петрушин М.А., Терещенко Е.В., Мельниченко П.И. и др. Успешное применение комбинированной экстракорпоральной поддержки жизнеобеспечения при лечении новой коронавирусной инфекции, осложненной развитием полиорганной дисфункции у беременной. Вестник анестезиологии и реаниматологии. 2021; 18 (4): 37–47 [Petrushin M.A., Tereschenko E.V., Melnichenko P.I. et al. The successful use of combined extracorporeal life support in treatment of the new coronavirus infection complicated by the development of multiple organ dysfunction in a pregnant woman. Messenger of Anesthesiology and Resuscitation. 2021; 18 (4): 37–47 (in Russ.)]. doi: 10.21292/2078-5658-2021-18-4-37-47
  12. Armstrong R.A., Kane A.D., Kursumovic E. et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021; 76 (4): 537–48. doi: 10.1111/anae.15425PMC8013495.9
  13. Wang Y., Lu X., Li Y. et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020; 201 (11): 1430–4. doi: 10.1164/rccm.202003-0736LE
  14. Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. и др. Международный регистр «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2» (АКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал. 2021; 26 (4): 4470 [Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. et al. International register «Dynamics analysis of comorbidities in SARS-CoV-2 survivors» (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Russian Journal of Cardiology. 2021; 26 (4): 4470 (in Russ.)]. doi: 10.15829/1560-4071-2021-4470
  15. Zheng Z., Peng F., Xu B. et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020; 81 (2): 16–25. doi: 10.1016/j.jinf.2020.04.021
  16. Намазова-Баранова Л.С., Мурашкин Н.Н., Иванов Р.А. Биологическая терапия в эру COVID-19. Вопросы современной педиатрии. 2020; 19 (2): 116–22 [Namazova-Baranova L.S., Murashkin N.N., Ivanov R.A. Biological Therapy During COVID-19. Current Pediatrics. 2020; 19 (2): 116–22 (in Russ.)]. doi: 10.15690/vsp.v19i2.2104
  17. Самигуллина Р.Р., Мазуров В.И., Трофимов Е.А. Особенности комплексной терапии иммуновоспалительных ревматических заболеваний в условиях пандемии COVID-19. РМЖ. Медицинское обозрение. 2021; 5 (5): 260–7 [Samigullina R.R., Mazurov V.I., Trofimov E.A. Features of complex therapy of immuno-inflammatory rheumatic diseases in the conditions of the COVID-19. Russian Medical Journal. Medical review. 2021; 5 (5): 260–7 (in Russ.)]. doi: 10.32364/2587-6821-2021-5-5-260-267

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Markov model

Download (208KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies